SCHEMBL275836

SCHEMBL275836

O=C1Nc2cc(Cl)ccc2C1=Cc1cc(Cl)ccc1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MDM2 Q00987 4/20 0.55
▸ NPC1 O15118 1/20 0.55
▸ TUBB4A P04350 2/20 0.54
▸ TUBB P07437 2/20 0.54
▸ TUBA3C P0DPH7 2/20 0.54
▸ TUBA1B P68363 2/20 0.54
▸ TUBA4A P68366 2/20 0.54
▸ TUBB4B P68371 2/20 0.54
▸ TUBB3 Q13509 2/20 0.54
▸ TUBB2A Q13885 2/20 0.54
▸ TUBB8 Q3ZCM7 2/20 0.54
▸ TUBA3E Q6PEY2 2/20 0.54
▸ TUBA1A Q71U36 2/20 0.54
▸ TUBA1C Q9BQE3 2/20 0.54
▸ TUBB6 Q9BUF5 2/20 0.54
▸ TUBB2B Q9BVA1 2/20 0.54
▸ TUBB1 Q9H4B7 2/20 0.54
▸ LRRK2 Q5S007 3/20 0.53
▸ CES1 P23141 1/20 0.53
▸ PSEN1 P49768 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL275835 1.00 MDM2 (0.55) MDM2NPC1TUBB4ATUBBTUBA3C
SCHEMBL276805 0.93 MDM2 (0.55) MDM2NPC1TUBB4ATUBBTUBA3C
SCHEMBL276804 0.93 MDM2 (0.55) MDM2NPC1TUBB4ATUBBTUBA3C
SCHEMBL14673914 0.90 NPC1 (0.70) MDM2NPC1TUBB4ATUBBTUBA3C
SCHEMBL14673913 0.90 NPC1 (0.70) MDM2NPC1TUBB4ATUBBTUBA3C
Tert-Butyl Formate SCHEMBL27817234 0.88 MDM2 (0.51) MDM2NPC1TUBB4ATUBBTUBA3C
SCHEMBL13929330 0.87 MDM2 (0.56) MDM2TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL12527251 0.86 MDM2 (0.54) MDM2NPC1TUBB4ATUBBTUBA3C
SCHEMBL29443831 0.86 MDM2 (0.54) MDM2NPC1TUBB4ATUBBTUBA3C
SCHEMBL13452982 0.86 MDM2 (0.54) MDM2NPC1TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 — — US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 — — EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 — — EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 — — WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT MDM2 918/4885NPC1 702/4885TUBB4A 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback